Drug interaction between tacrolimus and nilotinib in a patient with chronic myeloid leukemia after renal transplant

Nilotinib, a BCR‐ABL tyrosine kinase inhibitor, is a known inhibitor of CYP3A4 and could increase the concentration of drugs metabolized by CYP3A4. An immunosuppressive drug for nilotinib‐treated patients following transplant should be administered with careful pharmacokinetic monitoring because of...

Descripción completa

Detalles Bibliográficos
Autores principales: Onaka, Takashi, Takahashi, Naoto, Miura, Masatomo, Yonezawa, Akihito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412900/
https://www.ncbi.nlm.nih.gov/pubmed/28469859
http://dx.doi.org/10.1002/ccr3.900
Descripción
Sumario:Nilotinib, a BCR‐ABL tyrosine kinase inhibitor, is a known inhibitor of CYP3A4 and could increase the concentration of drugs metabolized by CYP3A4. An immunosuppressive drug for nilotinib‐treated patients following transplant should be administered with careful pharmacokinetic monitoring because of its interaction with nilotinib.

Ejemplares similares